Public Misunderstandings Around Clinical Trials
"What does the general public not understand the most about clinical trials?" is the question we posed to three industry professionals at DIA 2023.
"What does the general public not understand the most about clinical trials?" is the question we posed to three industry professionals. And their answers span only a few of the challenges that remain in patient education and knowledge about the clinical research enterprise.
In this video, Kenneth Getz, Executive Director and Professor, Tufts Center for the Study of Drug Development and Founder, Board Chair, CISCRP; Janice Chang, CEO of TransCelerate BioPharma, and Greg Ball, Safety Data Scientist and founder, ASAP Process Consulting present their views on the topic.
Industry Assessment of Risk-Based Quality Management Emphasizes Value of Adoption
April 4th 2024A study conducted by the Tufts CSDD in collaboration with CluePoints and PwC revealed that slightly more than half of sponsors and contract research organizations have adopted risk-based quality management approaches.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.
